731 - CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)

Thursday, October 20, 2022

2:00 PM – 2:15 PM US ET

Location: 144 ABC

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Presenting Author(s)

Paul C. McGovern, MD

Senior Vice President, Medical Sciences
Venatorx Pharmaceuticals
Malvern, PA, United States

Disclosure: Disclosure(s): Paratek Pharmaceuticals: Stocks/Bonds (); Venatorx Pharmaceuticals: employee (), Stocks/Bonds ()

Co-Author(s)

FW

Florian Wagenlehner, MD

Justuf Liebeg University Diessen
Diessen, Hessen, Germany

Disclosure: Disclosure(s): Glaxo Smith Kline: Advisor/Consultant (); Spero Pharmaceuticals: Advisor/Consultant (); Venatorx Pharmaceuticals: Advisor/Consultant ()
LG

Leanne Gasink, MD, MSCE

LBG Consulting
Saint Davids, Pennsylvania, United States

Disclosure: Disclosure(s): Amplyx Pharmaceuticals: Advisor/Consultant (); CSL Behring: Advisor/Consultant (); Pfizer: Advisor/Consultant (); Spero Therapeutics: Advisor/Consultant (); Venatorx Pharmaceuticals: Advisor/Consultant (); Vera Therapeutics: Advisor/Consultant ()
GM

Greg Moeck, PhD

Vice President, Microbiology
Venatorx Pharmaceuticals
Malvern, Pennsylvania, United States

Disclosure: Disclosure(s): Venatorx Pharmaceuticals: Employee (), Stocks/Bonds ()
PM

Patrick L. McLeroth, MD

VP, TA Head Infectious Disease and Critical Care
Labcorp
Princeton, New Jersey, United States

Disclosure: Disclosure(s): Labcorp: Full time employee (), Stocks/Bonds ()
MD

Mary Beth Dorr, PhD

Venatorx
Malvern, Pennsylvania, United States

Disclosure: Disclosure(s): Merck: Past employee (), Stocks/Bonds (); Pfizer: Stocks/Bonds (); Venatorx: Employee ()
AD

Aaron Dane, MSc

Director
Danestat Consulting Limited
Macclesfield, England, United Kingdom

Disclosure: Disclosure(s): Amplyx: Advisor/Consultant (); AN2 therapeutics: Advisor/Consultant (); Artizan: Advisor/Consultant (); Cidara: Advisor/Consultant (); ContraFect: Advisor/Consultant (); Correvio: Advisor/Consultant (); Davolterra: Advisor/Consultant (); Destiny Pharma: Advisor/Consultant (); Entasis: Advisor/Consultant (); F2G Limited: Advisor/Consultant (); GSK: Advisor/Consultant (); Humanigen: Advisor/Consultant (); Kymab: Advisor/Consultant (); Modis: Advisor/Consultant (); Orca: Advisor/Consultant (); Pfizer: Advisor/Consultant (); Phico: Advisor/Consultant (); Pled Pharma: Advisor/Consultant (); Rare Thyroid: Advisor/Consultant (); Roche: Advisor/Consultant (); Scynexis: Advisor/Consultant (); Sinovent: Advisor/Consultant (); Spero Therapeutics: Advisor/Consultant (); Transcrip: Advisor/Consultant (); Venatorx: Advisor/Consultant ()
TH

Tim Henkel, MD, PhD

Dr.
Venatorx Pharmaceuticals
Malvern, Pennsylvania, United States

Disclosure: Disclosure(s): Venatorx Pharmaceuticals: Stocks/Bonds ()

Disclosure(s):

Paul C. McGovern, MD: Paratek Pharmaceuticals: Stocks/Bonds (); Venatorx Pharmaceuticals: employee (), Stocks/Bonds ()

Florian Wagenlehner, MD: Glaxo Smith Kline: Advisor/Consultant (); Spero Pharmaceuticals: Advisor/Consultant (); Venatorx Pharmaceuticals: Advisor/Consultant ()

Leanne Gasink, MD, MSCE: Amplyx Pharmaceuticals: Advisor/Consultant (); CSL Behring: Advisor/Consultant (); Pfizer: Advisor/Consultant (); Spero Therapeutics: Advisor/Consultant (); Venatorx Pharmaceuticals: Advisor/Consultant (); Vera Therapeutics: Advisor/Consultant ()

Greg Moeck, PhD: Venatorx Pharmaceuticals: Employee (), Stocks/Bonds ()

Patrick L. McLeroth, MD: Labcorp: Full time employee (), Stocks/Bonds ()

Mary Beth Dorr, PhD: Merck: Past employee (), Stocks/Bonds (); Pfizer: Stocks/Bonds (); Venatorx: Employee ()

Aaron Dane, MSc: Amplyx: Advisor/Consultant (); AN2 therapeutics: Advisor/Consultant (); Artizan: Advisor/Consultant (); Cidara: Advisor/Consultant (); ContraFect: Advisor/Consultant (); Correvio: Advisor/Consultant (); Davolterra: Advisor/Consultant (); Destiny Pharma: Advisor/Consultant (); Entasis: Advisor/Consultant (); F2G Limited: Advisor/Consultant (); GSK: Advisor/Consultant (); Humanigen: Advisor/Consultant (); Kymab: Advisor/Consultant (); Modis: Advisor/Consultant (); Orca: Advisor/Consultant (); Pfizer: Advisor/Consultant (); Phico: Advisor/Consultant (); Pled Pharma: Advisor/Consultant (); Rare Thyroid: Advisor/Consultant (); Roche: Advisor/Consultant (); Scynexis: Advisor/Consultant (); Sinovent: Advisor/Consultant (); Spero Therapeutics: Advisor/Consultant (); Transcrip: Advisor/Consultant (); Venatorx: Advisor/Consultant ()

Tim Henkel, MD, PhD: Venatorx Pharmaceuticals: Stocks/Bonds ()